Renowned nephrologist and quality of care advocate will lead clinical programs and provider teams in delivering evidence-based, patient-centered care DENVER–(BUSINESS WIRE)–Strive Health, the national leader in value-based kidney care, welcomes Keith Bellovich, D.O., as its Chief Nephrologist. In this role, Dr. Bellovich will partner with the Chief Clinical Officer and other clinical leadership to drive … [Read more…]

Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations Participation from leading new investors and renewed commitment from long-time supporters signals strong confidence in Orum’s scientific direction, providing a solid foundation for the company’s next stage … [Read more…]

TOKYO–(BUSINESS WIRE)–3D Investment Partners Pte. Ltd. (together with the Fund, “3D” or the “Company”) provides discretionary investment management services to an investment fund which is a shareholder of Toho Holdings Co., Ltd. (TOKYO: 8129, “Toho HD”) (collectively referred to “3D” or “we” together with the investment fund) sent an open letter to the outside directors … [Read more…]

CHICAGO–(BUSINESS WIRE)–Cosan, a connected chronic care management company helping providers extend care beyond the clinic, today announced a $15 million strategic growth equity investment led by Ziegler Link-age Funds and Specialty Alliance, the nation’s largest provider of specialty care and a long-standing Cosan partner. The investment accelerates Cosan’s expansion of its AI-enabled, human-led virtual care … [Read more…]

SHORT HILLS, N.J.–(BUSINESS WIRE)–#healthcare–FemHealth Ventures, a leading women’s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm’s assets under management to $100 million across two funds and further solidifies FemHealth Ventures’ position as … [Read more…]

MADISON, Wis.–(BUSINESS WIRE)–Navitus, the nation’s first and largest transparent, pass-through pharmacy benefit manager (PBM), today announced the expanded implementation of Banjo Health. Banjo is an advanced automation platform with artificial intelligence (AI) capabilities designed to modernize and simplify prior authorization workflows that are central to pharmacy benefits management. Now implemented across employer and health plan … [Read more…]

Retailer and Market Demands Drive Rapid Traceability Adoption SALT LAKE CITY–(BUSINESS WIRE)–ReposiTrak (NYSE: TRAK), the industry leader in food traceability and regulatory compliance, announced that the push for traceability is now being driven by market forces rather than federal timelines. During a recent MorningNewsBeat interview, ReposiTrak Chairman and CEO Randy Fields and Affiliated Foods, Inc., … [Read more…]

TAIPEI, Taiwan–(BUSINESS WIRE)–Taiwan has achieved the World Health Organization’s (WHO) goal of eliminating Hepatitis C by 2025, reaching this milestone ahead of the global timeline. Through cross-sectoral collaboration from central to local levels, the nation has established an integrated strategy covering prevention, screening, and treatment. The results have been outstanding, with all key indicators surpassing … [Read more…]

Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of action and improvement of itch and sleep disturbance in patients with moderate-to-severe atopic dermatitis and prurigo nodularis1 Significant improvements in itch were observed as early as … [Read more…]

Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based on SWIFT trials showing significantly lower rate of annualized asthma exacerbations in patients receiving depemokimab versus placebo SWIFT data included reduction in exacerbations requiring hospitalization and/or emergency department visits with depemokimab An … [Read more…]